PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

This is an open-label, non-randomized, controlled, single-center, phase II study to compare the efficacy and safety of neoadjuvant PD-L1/PD-1 inhibitor + chemotherapy (carboplatin/cisplatin + etoposide) with chemotherapy (carboplatin/cisplatin + etoposide) alone followed by radical surgery and adjuvant treatment as perioperative therapy in patients with limited-stage SCLC.

NCT Number	NCT06375109
Lead Sponsor	Beijing Chest Hospital, Capital Medical University
Conditions	Limited-stage Small-cell Lung Cancer
Enrollment	60 participants
Start Date	2024-04-16
Primary Completion	2027-04-15 (estimated)
Study Completion	2029-04-15 (estimated)
Updated on ClinicalTrials.gov	2024-04-19